Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.83 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL383172 | 1.00 | TSHR (0.83) | TSHROR51E2TP53CYP2C9PDE4A | |
| Cadaverine Tartrate SCHEMBL10902643 | 1.00 | TSHR (0.83) | TSHROR51E2TP53CYP2C9PDE4A | |
| Cadaverine Tartrate SCHEMBL28611173 | 1.00 | TSHR (0.83) | TSHROR51E2TP53CYP2C9PDE4A | |
| Cadaverine Tartrate SCHEMBL445051 | 1.00 | TSHR (0.83) | TSHROR51E2TP53CYP2C9PDE4A | |
| Cadaverine Tartrate SCHEMBL546246 | 1.00 | TSHR (0.83) | TSHROR51E2TP53CYP2C9PDE4A | |
| Cadaverine Tartrate SCHEMBL27327211 | 0.96 | TSHR (0.77) | TSHROR51E2TP53CYP2C9PDE4A | |
| Cadaverine Tartrate SCHEMBL22325478 | 0.96 | TSHR (0.77) | TSHROR51E2TP53CYP2C9PDE4A | |
| Cadaverine Tartrate SCHEMBL1223376 | 0.96 | TSHR (0.77) | TSHROR51E2TP53CYP2C9PDE4A | |
| Cadaverine Tartrate SCHEMBL7571450 | 0.96 | TSHR (0.77) | TSHROR51E2TP53CYP2C9PDE4A | |
| Cadaverine Tartrate SCHEMBL25307085 | 0.96 | TSHR (0.91) | TSHROR51E2TP53CYP2C9PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119162482-A | Three-dimensional continuous net-shaped composite functional material and preparation method and application thereof | 华中科技大学 | 2024-12-20 | — | — | CN | claimed |
| CN-113980123-A | Method for decoppering horseshoe crab hemocyanin and application thereof | 广东海洋大学 | 2022-01-28 | — | — | CN | claimed |
| EP-4673424-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | Regeneron Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025106480-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250019381-A1 | PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONE | CARDURION PHARMACEUTICALS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-119162482-A | Three-dimensional continuous net-shaped composite functional material and preparation method and application thereof | 华中科技大学 | 2024-12-20 | — | — | CN | disclosed |
| CN-115747913-B | Treatment method for copper surface of inner layer of printed circuit board | 广州广合科技股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024182268-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-118488830-A | Levonorgestrel butyrate formulations and methods relating thereto | 美国政府(由卫生和人类服务部的部长所代表) | 2024-08-13 | — | — | CN | disclosed |
| CN-115746003-B | Methods of making and using PDE9 inhibitors | 卡都瑞恩医药公司 | 2024-08-09 | — | — | CN | disclosed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2006-05-11 | — | — | US | disclosed |
| EP-1628533-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-03-01 | — | — | EP | disclosed |
| CN-1596255-A | Heterocyclic compounds with potent chemokine receptor binding | ANORMED INC (CA) | 2005-03-16 | — | — | CN | disclosed |
| WO-2004106493-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| EP-0790332-B1 | A non-cyanide brass plating bath and a method of making metallic foil having a brass layer using the non-cyanide brass plating bath | GA TEK INC (US) | 2001-07-18 | — | — | EP | disclosed |
| US-5762778-A | Non-cyanide brass plating bath and a method of making metallic foil having a brass layer using the non-cyanide brass plating bath | GOULD ELECTRONICS INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0790332-A1 | A non-cyanide brass plating bath and a method of making metallic foil having a brass layer using the non-cyanide brass plating bath | GOULD ELECTRONICS INC. (US) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | TSHR 1980/4885OR51E2 4700/4885TP53 1105/4885 |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | TSHR 1370/4885OR51E2 153/4885TP53 1336/4885 |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | TSHR 1370/4885OR51E2 153/4885TP53 1336/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | TSHR 1370/4885OR51E2 153/4885TP53 1336/4885 |
| US-20250019381-A1 | PROCESS FOR THE SYNTHESIS OF 6-((3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-3-(TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-a]PYRAZIN-8-ONE | CDK8, PRMT8, DHPS | TSHR 2020/4885OR51E2 4782/4885TP53 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.